Listed

Graftech International Ltd: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 3, 2020 and accepted by EDGAR at Nov 3, 2020, 17:01 ET.

Share

Management's discussion and analysis

As filed, 41,785 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company

GrafTech is a leading manufacturer of graphite electrodes, the critical consumable for the electric arc furnace industry. We are the only graphite electrode producer that is substantially vertically integrated into petroleum needle coke, a key raw material for graphite electrodes. Vertical integration has allowed us to adopt a commercial strategy with long-term, fixed price, fixed volume, take-or-pay contracts providing earnings stability and visibility. These contracts define volumes and prices, along with price-escalation mechanisms for inflation, and include significant termination payments (typically, 50% to 70% of remaining contracted revenue) and, in certain cases, parent guarantees and collateral arrangements to manage our customer credit risk.

The environmental and economic advantages of electric arc furnace steel production positions both that industry and the graphite electrode industry for continued long-term growth.

We believe GrafTech's leadership position, strong cash flows, and advantaged low cost structure and vertical integration are sustainable competitive advantages. Our services and solutions we provide will position our customers and us for a better future.

COVID-19 and Operational Update

GrafTech continues to proactively manage through the COVID-19 crisis. Our executive-led COVID-19 response team meets three times per week to monitor the ongoing situation and respond as needed.

Our plants have remained operational through the current pandemic and maintained a 98% on-time delivery rate. Our global footprint gives us the flexibility to move or adjust production if needed.

We continue to focus on containing our costs and aligning production to current sales levels for the remainder of the year. We expect to meet our reduced full year capital expenditure estimate of approximately $35 million.

Commercial Update

GrafTech services customers at over 300 locations across the globe, all of which have been impacted by COVID-19. We are seeing a measured recovery in the global steel markets compared to the second quarter, with each region recovering at different rates, and anticipate this will have a positive influence on graphite electrode demand. In the third quarter, the global (ex-China) steel market capacity utilization rate improved to over 60%. In the U.S., the third quarter capacity utilization rate was approximately 64%. By late October, the capacity utilization rate in the U.S. steel market approached 70%.

The commercial team has worked diligently to achieve solid results in the current environment. Year-to-date sales volumes through the third quarter were 98 thousand metric tons ("MT"), consisting of LTA volumes of 82 thousand MT and non-LTA volumes of 16 thousand MT.

During the third quarter, our average price from LTAs declined slightly to approximately $9,300 per MT, reflecting the impacts of product mix, LTA modifications and other adjustments. Due to favorable mix in the quarter, the average price for our non-LTA business increased slightly to approximately $5,700 per MT. However, as anticipated, we believe the general spot price of graphite electrodes continued to trend lower during the third quarter. Given the continuing uncertainty caused by the pandemic and the macro-economic headwinds we and our customers face, we expect overall demand and pricing for our graphite electrodes to remain low for the remainder of 2020 as our customers continue to work through their existing graphite electrode inventories.

The current market conditions are challenging for our customers, including those with LTAs, and we have some customers that are continuing to struggle to take their committed volumes. This is causing some non-performance and disputes, including a few arbitrations associated with, among other things, efforts to modify existing contracts. As such, we will continue to work to preserve our rights under the LTAs.

We are working hard with our valued customers to develop mutually beneficial solutions and have successfully negotiated LTA modifications with several of these customers during the third quarter. We are able to provide near-term relief in exchange for additional contractual commitments going forward. We expect to continue to finalize more of these beneficial negotiations in the coming months.

Capital Structure and Capital Allocation

During the third quarter, we reduced our debt by approximately $150 million. After the quarter end, we further reduced our debt by an additional $60 million, bringing 2020 debt reduction to $313 million through the end of October. We will continue to prioritize balance sheet flexibility and expect to use the majority of fourth quarter incremental free cash flow to reduce debt.

Outlook

For the remainder of 2020, we anticipate our full year LTA sales volumes to be above the midpoint of the expected range of 100 thousand - 115 thousand MT. We now expect our full year LTA revenue will be between $1,000 million and $1,080 million in 2020.

With the LTA modifications and ongoing customer discussions, we are able to provide estimated shipments of graphite electrodes for the final two years of the initial term under our LTAs and for the years 2023 through 2024 as follows:

2021 2022 2023 through 2024
Estimated LTA volume(1) 98-108 95-105 35-45
Estimated LTA revenue(2) $925-$1,025 $910-$1,010 $350-$450(3)

(1) In thousands of metric tons

(2) In millions

(3) Includes expected termination fees from a few customers that have failed to meet certain obligations under their LTAs

Key metrics used by management to measure performance

In addition to measures of financial performance presented in our Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("GAAP"), we use certain other financial measures and operating metrics to analyze the performance of our company. The “non-GAAP” financial measures consist of EBITDA and adjusted EBITDA, which help us evaluate growth trends, establish budgets, assess operational efficiencies and evaluate our overall financial performance. The key operating metrics consist of sales volume, production volume, production capacity and capacity utilization.

Key financial measures

(in thousands)

For the Three Months Ended September 30, 2020 2019 For the Nine Months Ended September 30, 2020 2019
Net sales $286,987 $420,797 $886,351 $1,376,181
Net income 94,234 175,876 309,278 569,680
EBITDA (1) 150,960 242,026 483,634 802,569
Adjusted EBITDA (1) 153,105 245,454 483,408 813,673

(1) Non-GAAP financial measures; see below for information and a reconciliation of EBITDA and adjusted EBITDA to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP.

Key operating metrics

(in thousands, except price data)

For the Three Months Ended September 30, 2020 2019 For the Nine Months Ended September 30, 2020 2019
Sales volume (MT)(1) 33 40 98 130
Production volume (MT)(2) 32 40 98 136
Production capacity excluding St. Marys (MT)(3)(4) 48 48 150 150
Capacity utilization excluding St. Marys (3)(5) 67% 83% 65% 91%
Total production capacity (MT)(4)(6) 55 55 171 171
Total capacity utilization(5)(6) 58% 73% 57% 80%

25

(1) Sales volume reflects only graphite electrodes manufactured by GrafTech.

(2) Production volume reflects graphite electrodes we produced during the period.

(3) In the first quarter of 2018, our St. Marys facility began graphitizing a limited amount of electrodes sourced from our Monterrey, Mexico facility.

(4) Production capacity reflects expected maximum production volume during the period under normal operating conditions, standard product mix and expected maintenance outage. Actual production may vary.

(5) Capacity utilization reflects production volume as a percentage of production capacity.

(6) Includes graphite electrode facilities in Calais, France; Monterrey, Mexico; Pamplona, Spain and St. Marys, Pennsylvania.

Non-GAAP financial measures

In addition to providing results that are determined in accordance with GAAP, we have provided certain financial measures that are not in accordance with GAAP. EBITDA and adjusted EBITDA are non-GAAP financial measures. We define EBITDA, a non-GAAP financial measure, as net income or loss plus interest expense, minus interest income, plus income taxes, and depreciation and amortization. We define adjusted EBITDA as EBITDA plus any pension and other post-employment benefit ("OPEB") plan expenses, initial and follow-on public offering and related expenses, non-cash gains or losses from foreign currency remeasurement of non-operating assets and liabilities in our foreign subsidiaries where the functional currency is the U.S. dollar, related party Tax Receivable Agreement adjustment, stock-based compensation and non-cash fixed asset write-offs. Adjusted EBITDA is the primary metric used by our management and our Board of Directors to establish budgets and operational goals for managing our business and evaluating our performance.

We monitor adjusted EBITDA as a supplement to our GAAP measures, and believe it is useful to present to investors, because we believe that it facilitates evaluation of our period-to-period operating performance by eliminating items that are not operational in nature, allowing comparison of our recurring core business operating results over multiple periods unaffected by differences in capital structure, capital investment cycles and fixed asset base. In addition, we believe adjusted EBITDA and similar measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance and debt-service capabilities.

Our use of adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;
  • adjusted EBITDA does not reflect our cash expenditures for capital equipment or other contractual commitments, including any capital expenditure requirements to augment or replace our capital assets;
  • adjusted EBITDA does not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness;
  • adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to us;
  • adjusted EBITDA does not reflect expenses relating to our pension and OPEB plans;
  • adjusted EBITDA does not reflect the non-cash gains or losses from foreign currency remeasurement of non-operating assets and liabilities in our foreign subsidiaries where the functional currency is the U.S. dollar;
  • adjusted EBITDA does not reflect initial and follow-on public offering and related expenses;
  • adjusted EBITDA does not reflect related party Tax Receivable Agreement adjustments;
  • adjusted EBITDA does not reflect stock-based compensation or the non-cash write-off of fixed assets; and
  • other companies, including companies in our industry, may calculate EBITDA and adjusted EBITDA differently, which reduces its usefulness as a comparative measure.

In evaluating EBITDA and adjusted EBITDA, you should be aware that in the future, we will incur expenses similar to the adjustments in this presentation. Our presentations of EBITDA and adjusted EBITDA should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider EBITDA and adjusted EBITDA alongside other financial performance measures, including our net income (loss) and other GAAP measures.

The following table reconciles our non-GAAP key financial measures to the most directly comparable GAAP measures:

(in thousands)

For the Three Months Ended September 30, 2020 2019 For the Nine Months Ended September 30, 2020 2019
Net income $94,234 $175,876 $309,278 $569,680
Add:
Depreciation and amortization 16,241 15,357 45,074 46,387
Interest expense 22,474 31,803 69,026 98,472
Interest income (93) (1,765) (1,582) (2,910)
Income taxes 18,104 20,755 61,838 90,940
EBITDA 150,960 242,026 483,634 802,569
Adjustments:
Pension and OPEB plan expenses (1) 583 800 1,666 2,397
Initial and follow-on public offering and related expenses (2) — 160 4 1,409
Non-cash loss (gain) on foreign currency remeasurement (3) 798 (185) (441) 842
Stock-based compensation (4) 764 706 1,891 1,568
Non-cash fixed asset write-off (5) — 1,947 — 4,888
Related party Tax Receivable Agreement adjustment(6) — — (3,346) —
Adjusted EBITDA $153,105 $245,454 $483,408 $813,673

(1) Service and interest cost of our OPEB plans. Also includes a mark-to-market loss (gain) for plan assets as of December of each year.

(2) Legal, accounting, printing and registration fees associated with the initial and follow-on public offering and related expenses.

(3) Non-cash gains and losses from foreign currency remeasurement of non-operating assets and liabilities of our non-U.S. subsidiaries where the functional currency is the U.S. dollar.

(4) Non-cash expense for stock-based compensation grants.

(5) Non-cash fixed asset write-off recorded for obsolete assets.

(6) Non-cash expense adjustment for future payment to our sole pre-IPO stockholder for tax assets that are expected to be utilized.

Key Operating Metrics

In addition to measures of financial performance presented in accordance with GAAP, we use certain operating metrics to analyze the performance of our company. The key operating metrics consist of sales volume, production volume, production capacity and capacity utilization. These metrics align with management's assessment of our revenue performance and profit margin and will help investors understand the factors that drive our profitability.

Sales volume reflects only graphite electrodes manufactured by GrafTech. For a discussion of our revenue recognition policy, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies-Revenue Recognition.” in our Annual Report on Form 10-K. Sales volume helps investors understand the factors that drive our net sales.

Production volume reflects graphite electrodes produced during the period. Production capacity reflects expected maximum production volume during the period under normal operating conditions, standard product mix and expected maintenance downtime. Capacity utilization reflects production volume as a percentage of production capacity. Production volume, production capacity and capacity utilization help us understand the efficiency of our production, evaluate cost of sales and consider how to approach our contract initiative.

Results of Operations

The Three Months Ended September 30, 2020 Compared to the Three Months Ended September 30, 2019

The tables presented in our period-over-period comparisons summarize our Condensed Consolidated Statements of Operations and illustrate key financial indicators used to assess the consolidated financial results. Throughout our Management's Discussion and Analysis ("MD&A"), insignificant changes may be deemed not meaningful and are generally excluded from the discussion.

(Dollars in thousands)

For the Three Months Ended September 30, 2020 2019 Increase/ Decrease % Change
Net sales $286,987 $420,797 $(133,810) (32)%
Cost of sales 131,862 178,497 (46,635) (26)%
Gross profit 155,125 242,300 (87,175) (36)%
Research and development 650 611 39 6%
Selling and administrative expenses 19,062 15,708 3,354 21%
Operating income 135,413 225,981 (90,568) (40)%
Other expense (income), net 694 (688) 1,382 (201)%
Interest expense 22,474 31,803 (9,329) (29)%
Interest income (93) (1,765) 1,672 (95)%
Income before provision for income taxes 112,338 196,631 (84,293) (43)%
Provision for income taxes 18,104 20,755 (2,651) (13)%
Net income $94,234 $175,876 $(81,642) (46)%

Net sales. Net sales decreased from $420.8 million in the three months ended September 30, 2019 to $287.0 million in the three months ended September 30, 2020. Lower net sales reflect an 18% decrease in sales volume driven primarily by the impact of COVID-19 on steel production levels and continued customer inventory destocking. We realized lower average spot prices resulting from this lower demand. Prices achieved from our long-term agreements ("LTAs") were also lower in the three months ended September 30, 2020 as compared to the same period of 2019 due primarily to mix, LTA modifications and other adjustments.

Cost of sales. We experienced a decrease in cost of sales from $178.5 million in the three months ended September 30, 2019 to $131.9 million in the three months ended September 30, 2020, primarily due to the 18% decrease in sales volume of manufactured electrodes. Additionally, cost of sales was lower due to less usage of third-party needle coke.

Selling and administrative expenses. Selling and administrative expenses increased from $15.7 million in the three months ended September 30, 2019 to $19.1 million in the three months ended September 30, 2020 primarily due to higher legal costs.

Interest expense. Interest expense decreased from $31.8 million in the three months ended September 30, 2019 to $22.5 million in the three months ended September 30, 2020, primarily due to lower interest rates and lower average borrowings. During the three months ended September 30, 2020, we reduced our term loan by $150.0 million. We realized a $0.8 million benefit to interest expense resulting from gains on certain of these transactions in the three months ended September 30, 2020.

Provision for income taxes. The following table summarizes the expense for income taxes:

(Dollars in thousands)

For the Three Months Ended September 30, 2020 2019
Tax expense $18,104 $20,755
Pretax income 112,338 196,631
Effective tax rates 16.1% 10.6%

The effective tax rate for the three months ended September 30, 2020 was 16.1%. This rate differs from the U.S. statutory rate of 21% primarily due to worldwide earnings from various countries taxed at different rates which are offset by the net increase related to the U.S. taxation of global intangible low taxed income ("GILTI") and the Section 250 Deduction and Foreign Tax Credits ("FTC").

The effective tax rate for the three months ended September 30, 2019 was 10.6%. This rate differs from the U.S. statutory rate of 21% primarily due to worldwide earnings from various countries taxed at different rates.

Tax expense decreased from $20.8 million for the three months ended September 30, 2019 to $18.1 million for the three months ended September 30, 2020. This change is primarily related to the reduction in profits.

The Nine Months Ended September 30, 2020 Compared to the Nine Months Ended September 30, 2019

The tables presented in our period-over-period comparisons summarize our Condensed Consolidated Statements of Operations and illustrate key financial indicators used to assess the consolidated financial results. Throughout our MD&A, insignificant changes may be deemed not meaningful and are generally excluded from the discussion.

(Dollars in thousands)

For the Nine Months Ended September 30, 2020 2019 Increase/ Decrease % Change
Net sales $886,351 $1,376,181 $(489,830) (36)%
Cost of sales 401,379 571,068 (169,689) (30)%
Gross profit 484,972 805,113 (320,141) (40)%
Research and development 2,072 1,961 111 6%
Selling and administrative expenses 49,995 46,328 3,667 8%
Operating income 432,905 756,824 (323,919) (43)%
Other (income) expense (2,309) 642 (2,951) (460)%
Related party Tax Receivable Agreement benefit (3,346) — (3,346) N/A
Interest expense 69,026 98,472 (29,446) (30)%
Interest income (1,582) (2,910) 1,328 (46)%
Income before provision for income taxes 371,116 660,620 (289,504) (44)%
Provision for income taxes 61,838 90,940 (29,102) (32)%
Net income $309,278 $569,680 $(260,402) (46)%

Net sales. Net sales decreased by $489.8 million, or 36%, from $1,376.2 million in the nine months ended September 30, 2019 to $886.4 million in the nine months ended September 30, 2020. Lower net sales reflect a 25% decrease in sales volume driven primarily by the impact of COVID-19 on steel production levels and continued customer inventory destocking. Additionally, during the same period, spot prices declined significantly and we experienced a reduction in the resale of purchased electrodes.

Cost of sales. Cost of sales decreased by $169.7 million, or 30%, from $571.1 million in the nine months ended September 30, 2019 to $401.4 million in the nine months ended September 30, 2020. This decrease was primarily due to the

25% decrease in sales volume of manufactured electrodes, as well as less usage of third-party needle coke. Additionally, cost of sales was lower due to a reduction in the resale of purchased electrodes.

Selling and administrative expenses. Selling and administrative expenses increased from $46.3 million in the nine months ended September 30, 2019 to $50.0 million in the nine months ended September 30, 2020 primarily due to increased legal costs.

Other (income) expense. Other expense changed by $3.0 million, from an expense of $0.6 million in the nine months ended September 30, 2019 to income of $2.3 million in the nine months ended September 30, 2020. This change was primarily due to advantageous non-cash foreign currency impacts on non-operating assets and liabilities.

Related party Tax Receivable Agreement benefit. During the first quarter of 2020, the Company recorded an adjustment to our Related-party payable-Tax Receivable Agreement liability resulting in a benefit of $3.3 million due to the revised profit expectation for the year 2020, primarily caused by the COVID-19 pandemic.

Interest expense. Interest expense decreased by $29.4 million from $98.5 million in the nine months ended September 30, 2019 to $69.0 million in the same period of 2020, primarily due to lower interest rates and lower average borrowings. We made repayments of $125 million on our term loans in the first quarter of 2019 and $225 million in the fourth quarter of 2019. During the nine months ended September 30, 2020, we reduced our term loan by $253 million. We realized a $3.8 million benefit to interest expense resulting from gains on certain of these transactions in the nine months ended September 30, 2020.

Provision for income taxes. The following table summarizes the expense for income taxes:

(Dollars in thousands)

For the Nine Months Ended September 30, 2020 2019
Tax expense $61,838 $90,940
Pre-tax income 371,116 660,620
Effective tax rates 16.7% 13.8%

The effective tax rate for the nine months ended September 30, 2020 was 16.7%. This rate differs from the U.S. statutory rate of 21% primarily due to worldwide earnings from various countries taxed at different rates, which was offset by a net increase related to the U.S. taxation of GILTI and FTC.

The tax expense decreased from $90.9 million for the nine months ended September 30, 2019 to $61.8 million for the nine months ended September 30, 2020 primarily from the decrease in earnings.

The effective tax rate for the nine months ended September 30, 2019 was 13.8%. This rate differed from the U.S. statutory rate of 21% primarily due to worldwide earnings from various countries taxed at different rates.

GrafTech has considered the tax impact of COVID-19 legislation, including the U.S. Coronavirus Aid, Relief and Economic Security (CARES) Act and has concluded that there is no material tax impact. The Company continues to monitor the tax effects of any legislative changes.

Effects of Changes in Currency Exchange Rates

When the currencies of non-U.S. countries in which we have a manufacturing facility decline (or increase) in value relative to the U.S. dollar, this has the effect of reducing (or increasing) the U.S. dollar equivalent cost of sales and other expenses with respect to those facilities. In certain countries in which we have manufacturing facilities, and in certain export markets, we sell in currencies other than the U.S. dollar. Accordingly, when these currencies increase (or decline) in value relative to the U.S. dollar, this has the effect of increasing (or reducing) net sales. The result of these effects is to increase (or decrease) operating profit and net income.

Many of the non-U.S. countries in which we have a manufacturing facility have been subject to significant economic and political changes, which have significantly impacted currency exchange rates. We cannot predict changes in currency exchange rates in the future or whether those changes will have net positive or negative impacts on our net sales, cost of sales or net income.

The impact of these changes in the average exchange rates of other currencies against the U.S. dollar on our net sales was an increase of $2.5 million and $0.5 million for the three and nine months ended September 30, 2020, respectively, compared to the same period of 2019. The impact of these changes on our cost of sales was a decrease of $0.7 million and $5.0 million for the three and nine months ended September 30, 2020, respectively, compared to the same period of 2019.

We have in the past and may in the future use various financial instruments to manage certain exposures to risks caused by currency exchange rate changes, as described under “Part I, Item 3–Quantitative and Qualitative Disclosures about Market Risk.”

Liquidity and Capital Resources

Our sources of funds have consisted principally of cash flow from operations and debt, including our credit facilities (subject to continued compliance with the financial covenants and representations). Our uses of those funds (other than for operations) have consisted principally of dividends, capital expenditures, scheduled debt repayments, optional debt repayments, share repurchases and other obligations. Disruptions in the U.S. and international financial markets could adversely affect our liquidity and the cost and availability of financing to us in the future.

We believe that we have adequate liquidity to meet our needs. As of September 30, 2020, we had liquidity of $405.7 million, consisting of $246.9 million of availability under our 2018 Revolving Facility (subject to continued compliance with the financial covenants and representations) and cash and cash equivalents of $158.8 million. We had long-term debt of $1,564.4 million and short-term debt of $0.1 million as of September 30, 2020. As of December 31, 2019, we had liquidity of $327.8 million consisting of $246.9 million available on our 2018 Revolving Facility (subject to continued compliance with the financial covenants and representations) and cash and cash equivalents of $80.9 million. We had long-term debt of $1,812.7 million and short-term debt of $0.1 million as of December 31, 2019.

As of September 30, 2020 and December 31, 2019, $130.3 million and $41.4 million, respectively, of our cash and cash equivalents were located outside of the U.S. We repatriate funds from our foreign subsidiaries through dividends. All of our subsidiaries face the customary statutory limitation that distributed dividends do not exceed the amount of retained and current earnings. In addition, for our subsidiary in South Africa, the South Africa Central Bank requires that certain solvency and liquidity ratios remain above defined levels after the dividend distribution, which historically has not materially affected our ability to repatriate cash from this jurisdiction. The cash and cash equivalents balances in South Africa were $0.6 million and $0.8 million as of September 30, 2020 and December 31, 2019, respectively. Upon repatriation to the U.S., the foreign source portion of dividends we receive from our foreign subsidiaries is no longer subject to U.S. federal income tax as a result of The Tax Cuts and Jobs Act (the "Tax Act").

Cash flow and plans to manage liquidity. Our cash flow typically fluctuates significantly between quarters due to various factors. These factors include customer order patterns, fluctuations in working capital requirements, timing of tax payments, timing of capital expenditures, acquisitions, divestitures and other factors. Cash flow from operations is expected to remain at positive sustained levels due to the predictable earnings generated by our three-to-five-year sales contracts with our customers.

We had availability under the 2018 Revolving Facility of $246.9 million as of September 30, 2020 and December 31, 2019, which consisted of the $250 million limit reduced by $3.1 million of outstanding letters of credit.

On February 12, 2018, we entered into the 2018 Credit Agreement, which provides for the 2018 Revolving Facility and the 2018 Term Loan Facility. On February 12, 2018, our wholly owned subsidiary, GrafTech Finance, borrowed $1,500 million under the 2018 Term Loan Facility. The funds received were used to pay off our outstanding debt, including borrowings under our prior credit facility and the previously outstanding senior notes and accrued interest relating to those borrowings and the senior notes, declare and pay a dividend of $1,112 million to our sole pre-IPO stockholder, pay fees and expenses incurred in connection therewith and for other general corporate purposes.

On June 15, 2018, GrafTech entered into the First Amendment to its 2018 Credit Agreement. The First Amendment amends the 2018 Credit Agreement to provide for an additional $750 million in aggregate principal amount of the Incremental Term Loans to GrafTech Finance. The Incremental Term Loans increase the aggregate principal amount of term loans incurred by GrafTech Finance under the 2018 Credit Agreement from $1,500 million to $2,250 million. The Incremental Term Loans have the same terms as those applicable to the existing term loans under the 2018 Credit Agreement, including interest rate, payment and prepayment terms, representations and warranties and covenants. The Incremental Term Loans mature on February 12, 2025, the same date as the existing term loans. GrafTech paid an upfront fee of 1.00% of the aggregate principal amount of the Incremental Term Loans on the effective date of the First Amendment. The proceeds of the Incremental Term Loans were used to repay, in full, the $750 million of our existing debt to our sole pre-IPO stockholder.

On July 30, 2019, our Board of Directors authorized a program to repurchase up to $100 million of our outstanding common stock. We may purchase shares from time to time on the open market, including under Rule 10b5-1 and/or Rule 10b-18 plans. The amount and timing of repurchases are subject to a variety of factors including liquidity, stock price, applicable legal requirements, other business objectives and market conditions. We have repurchased 4,333,259 shares of common stock for a total purchase price of $40.9 million under this program since inception. There were no shares repurchased under this program during the three months ended September 30, 2020.

In April 2020, as a result of the deteriorating economic environment, our Board of Directors reduced our dividend rate to $0.01 per share or $0.04 on an annualized basis. We expect our Board of Directors to revisit the dividend level when economic conditions improve. There can be no assurance that we will pay dividends in the future in these amounts or at all. Our Board of Directors may change the timing and amount of any future dividend payments or eliminate the payment of future dividends in its sole discretion, without any prior notice to our stockholders. Our ability to pay dividends will depend upon many factors, including our financial position and liquidity, results of operations, legal requirements, restrictions that may be imposed by the terms of our current and future credit facilities and other debt obligations and other factors deemed relevant by our Board of Directors.

We repaid $350 million on our 2018 Term Loan Facility in 2019. During the three and nine months ended September 30, 2020, we retired $149.7 million and $253.0 million of principal of our term loans, respectively. Subsequent to September 30, 2020, we repaid an additional $60.0 million of our term loans. In light of the recent economic downturn, we are now prioritizing balance sheet flexibility and debt repayment. We anticipate using a majority of the cash flow that we generate to repay debt, but we will continue to examine opportunities to repurchase our common stock. As a result of government enacted COVID-19 relief in a foreign jurisdiction, we were able to defer a tax payment of approximately $50 million that was scheduled to be made in the first quarter of 2020 until the fourth quarter of 2020. During the nine months ended September 30, 2020, we paid $31.9 million to various tax collecting agencies worldwide.

Potential uses of our liquidity include dividends, share repurchases, capital expenditures, acquisitions, scheduled debt repayments, optional debt repayments and other general purposes. An improving economy, while resulting in improved results of operations, could increase our cash requirements to purchase inventories, make capital expenditures and fund payables and other obligations until increased accounts receivable are converted into cash. A downturn, including the current downturn caused by the COVID-19 pandemic, could significantly and negatively impact our results of operations and cash flows, which, coupled with increased borrowings, could negatively impact our credit ratings, our ability to comply with debt covenants, our ability to secure additional financing and the cost of such financing, if available.

In order to seek to minimize our credit risks, we may reduce our sales of, or refuse to sell (except for prepayment, cash on delivery or under letters of credit or parent guarantees), our products to some customers and potential customers. Our unrecovered trade receivables worldwide have not been material during the last two years individually or in the aggregate.

We manage our capital expenditures by taking into account quality, plant reliability, safety, environmental and regulatory requirements, prudent or essential maintenance requirements, global economic conditions, available capital resources, liquidity, long-term business strategy and return on invested capital for the relevant expenditures, cost of capital and return on invested capital of the Company as a whole and other factors.

Capital expenditures totaled $30.7 million in the nine months ended September 30, 2020. We previously reduced our planned capital expenditures for the full year by approximately one-half to a level of approximately $35 million and we remain committed to this goal. We are managing inventory levels to match demand. Due to timing of purchases, inventory levels increased during the first quarter of 2020. We expect overall inventory levels to decrease over the remainder of 2020.

In the event that operating cash flows fail to provide sufficient liquidity to meet our business needs, including capital expenditures, any such shortfall would need to be made up by increased borrowings under our 2018 Revolving Facility, to the extent available.

Cash Flows

The following table summarizes our cash flow activities:

(in millions)

Cash flow provided by (used in): For the Nine Months Ended September 30, 2020 2019
Operating activities $416.7 $584.8
Investing activities $(30.6) $(44.0)
Financing activities $(307.6) $(208.5)

Operating Activities

Cash flow from operating activities represents cash receipts and cash disbursements related to all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting net income (loss) for:

  • Non-cash items such as depreciation and amortization, impairment, post retirement obligations, and severance and pension plan changes;
  • Gains and losses attributed to investing and financing activities such as gains and losses on the sale of assets and unrealized currency transaction gains and losses; and
  • Changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.

The net impact of the changes in working capital (operating assets and liabilities), which are discussed in more detail below, include the impact of changes in: receivables, inventories, prepaid expenses, accounts payable, accrued liabilities, accrued taxes, interest payable and payments of other current liabilities.

During the nine months ended September 30, 2020, changes in working capital resulted in a net source of funds of $85.1 million, which was impacted by:

  • net cash inflows in accounts receivable of $78.4 million from the decrease in accounts receivable due to lower sales;
  • net cash inflows in inventory of $10.4 million from our efforts to reduce inventory levels and lower production levels;
  • net cash inflows of $5.4 million from the decrease in other current assets primarily due to value-added tax refunds received from foreign governments;
  • net cash inflows from increased income taxes payable of $16.0 million resulting from our ability to defer approximately $50.0 million of tax payment in a foreign jurisdiction resulting from government enacted COVID-19 relief, partially offset by lower required tax payments due to lower profitability; and
  • net cash outflows from decreases in accounts payable and accruals of $25.1 million, due to lower purchases of third-party needle coke and payments.

Uses of cash in the nine months ended September 30, 2020 included contributions to pension and other benefit plans of $5.3 million, cash paid for interest of $68.0 million, payments under our Tax Receivable Agreement of $27.9 million and taxes paid of $31.9 million.

During the nine months ended September 30, 2019, changes in working capital resulted in a net use of funds of $80.3 million, which was impacted by:

  • net cash outflows in accounts receivable of $20.7 million from the increase in accounts receivable due to the timing of sales and collections;
  • net cash outflows from increases in inventory of $19.9 million, due primarily to higher priced raw materials;
  • net cash inflows from the utilization of prepaid assets of $5.7 million;
  • net cash outflows from decreased income taxes payable of $28.2 million, resulting from required tax payments as our profitability has increased; and
  • net cash inflows from increases in accounts payable and accruals of $17.3 million, due to the timing of payments.

Uses of cash in the six months ended September 30, 2019 included contributions to pension and other benefit plans of $2.3 million, cash paid for interest of $93.6 million and taxes paid of $87.0 million.

Investing Activities

Net cash used in investing activities was $30.6 million during the nine months ended September 30, 2020, resulting from capital expenditures.

Net cash used in investing activities was $44.0 million during the nine months ended September 30, 2019, resulting from capital expenditures.

Financing Activities

Net cash outflow from financing activities was $307.6 million during the nine months ended September 30, 2020, which was the result of the repayment of $249.2 million on our Term Loans, $28.2 million of total dividends to stockholders and $30.1 million of stock repurchases.

Net cash outflow from financing activities was $208.5 million during the nine months ended September 30, 2019, which was the result of our $125.0 million payment on our Term Loan debt, $74.0 million of total dividends to stockholders and $9.5 million of stock repurchases.

Related Party Transactions

We have engaged in transactions with affiliates or related parties during 2020 and we expect to continue to do so in the future. These transactions include ongoing obligations under the Tax Receivable Agreement, Stockholders Rights Agreement and Registration Rights Agreement, each with Brookfield.

Recent Accounting Pronouncements

We discuss recently adopted accounting standards in Note 1, "Organization and Summary of Significant Accounting Policies" of the Notes to Condensed Consolidated Financial Statements.

Description of Our Financing Structure

We discuss our financing structure in more detail in Note 5, "Debt and Liquidity" of the Notes to Condensed Consolidated Financial Statements.

Market risk

As filed, 4,963 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are exposed to market risks, primarily from changes in interest rates, currency exchange rates, energy commodity prices and commercial energy rates. From time to time, we enter into transactions that have been authorized according to documented policies and procedures in order to manage these risks. These transactions primarily relate to financial instruments described below. Since the counterparties to these financial instruments are large commercial banks and similar financial institutions, we do not believe that we are exposed to material counterparty credit risk. We do not use financial instruments for trading purposes.

Our exposure to changes in interest rates results primarily from floating rate long-term debt tied to LIBO Rate or Euro LIBO Rate.

Our exposure to changes in currency exchange rates results primarily from:

  • sales made by our subsidiaries in currencies other than local currencies;
  • raw material purchases made by our foreign subsidiaries in currencies other than local currencies; and
  • investments in and intercompany loans to our foreign subsidiaries and our share of the earnings of those subsidiaries, to the extent denominated in currencies other than the U.S. dollar.

Our exposure to changes in energy commodity prices and commercial energy rates results primarily from the purchase or sale of refined oil products and the purchase of natural gas and electricity for use in our manufacturing operations.

Interest rate risk management. We periodically enter into agreements with financial institutions that are intended to limit our exposure to additional interest expense due to increases in variable interest rates. These instruments effectively cap our interest rate exposure. During the third quarter of 2019, we entered into interest rate swaps resulting in a net unrealized pre-tax loss of $13.3 million as of September 30, 2020 and net unrealized pre-tax gain of $2.9 million as of December 31, 2019.

Currency rate management. We enter into foreign currency derivatives from time to time to attempt to manage exposure to changes in currency exchange rates. These foreign currency derivatives, which include, but are not limited to, forward exchange contracts and purchased currency options, attempt to hedge global currency exposures. Forward exchange contracts are agreements to exchange different currencies at a specified future date and at a specified rate. Purchased currency options are instruments which give the holder the right, but not the obligation, to exchange different currencies at a specified rate at a specified date or over a range of specified dates. Forward exchange contracts and purchased currency options are carried at fair value.

The outstanding foreign currency derivatives represented $0.7 million pre-tax net gain as of September 30, 2020 and a net pre-tax gain of $0.2 million as of December 31, 2019.

Energy commodity management. We have entered into commodity derivative contracts to effectively fix some or all of our exposure to refined oil products. The outstanding commodity derivative contracts represented a net unrealized pre-tax loss of $8.9 million and $3.7 million as of September 30, 2020 and December 31, 2019, respectively.

Sensitivity analysis. We use sensitivity analysis to quantify potential impacts that market rate changes may have on the underlying exposures as well as on the fair values of our derivatives. The sensitivity analysis for the derivatives represents the hypothetical changes in value of the hedge position and does not reflect the related gain or loss on the forecasted underlying transaction.

A hypothetical increase in interest rates of 100 basis points (1%) would have increased our interest expense by $3.5 million, net of the impact of our interest rate swap, for the nine months ended September 30, 2020. The same 100 basis points increase would have resulted in an increase of $13.7 million in the fair value of our interest rate swap portfolio.

As of September 30, 2020, a 10% appreciation or depreciation in the value of the U.S. dollar against foreign currencies from the prevailing market rates would have resulted in a corresponding decrease of $5.3 million or a corresponding increase of $5.3 million, respectively, in the fair value of the foreign currency hedge portfolio.

A 10% increase or decrease in the value of the underlying commodity prices that we hedge would have resulted in a corresponding increase or decrease of $6.7 million in the fair value of the commodity hedge portfolio as of September 30, 2020. Because of the high correlation between the hedging instrument and the underlying exposure, fluctuations in the value of the instruments are generally offset by reciprocal changes in the value of the underlying exposure.

For further information related to the financial instruments described above, see Note 10 "Derivative Instruments" to the Notes to Condensed Consolidated Financial Statements.

Controls and procedures

As filed, 1,740 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures. Management is responsible for establishing and maintaining adequate disclosure controls and procedures at the reasonable assurance level. Disclosure controls and procedures are designed to ensure that information required to be disclosed by a reporting company in the reports that it files or submits under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by it in the reports that it files under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2020. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these controls and procedures were effective at the reasonable assurance level as of September 30, 2020.

Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2020 that materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 4,296 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following disclosure modifies the discussion of certain risks and uncertainties previously disclosed in Part I - Item 1A. of our Annual Report on Form 10-K. These risks and uncertainties, along with those previously disclosed, could materially adversely affect our business or financial results. Additional risks and uncertainties that are not presently known to us or that we deem immaterial may also impact our business or financial results.

The COVID-19 pandemic has had, and is expected to continue to have, an adverse impact on our business, results of operations, financial position and cash flows.

In December 2019, there was an outbreak of a novel strain of coronavirus ("COVID-19") identified in China that has since spread to nearly all regions of the world. The outbreak was subsequently declared a pandemic by the World Health Organization in March 2020. To date, the COVID-19 outbreak and preventative measures taken to contain or mitigate the outbreak have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas and significant disruption in the financial markets and economy both globally and in the U.S.

In response to the pandemic and related mitigation measures, we began implementing changes in our business in February 2020 to protect our employees and customers, and to support appropriate health and safety protocols, which included: (i) canceling travel and eliminating in-person meetings, (ii) working from home where possible, and (iii) establishing a "Safe-Work Playbook" for our sites. Our plant procedures include temperature measurements where permitted, personal protective equipment, mandatory use of gloves, social distancing, frequent cleaning and disinfecting and the use of daily check sheets to keep team members highly focused on these new procedures. As the pandemic continues, we continue to limit travel and have certain employees working from home on rotations so that all employees are not in our offices at the same time. While all of these measures have been necessary and appropriate, they have resulted in additional costs and have adversely impacted our business and financial performance.

While the outbreak had begun to subside in certain areas of the world where we operate and serve our customers, the infection rates in some of these areas have experienced a resurgence in the spread of COVID-19 and the infection rates in other areas continue to escalate. As a result, we are unable to predict the ultimate impact of the COVID-19 outbreak at this time. The pandemic has adversely affected, and is expected to continue to adversely affect, our business, results of operations, financial position and cash flows. Such effects may be material and the potential impacts include, but are not limited to:

  • adverse impact on our customers, and resultant impact on demand for our products;
  • disruptions at our facilities, including reductions in operating hours, labor shortages and changes in operating procedures, including for additional cleaning and disinfecting procedures;
  • disruptions in our supply chain due to transportation delays, travel restrictions, raw material cost increases and shortages, and closures of businesses or facilities;
  • reductions in our operating effectiveness due to workforce disruptions from COVID-19 restrictions and social distancing resulting from, among other things, “shelter in place” and “stay at home” orders, and the unavailability of key personnel necessary to conduct our business activities; and
  • volatility in the global financial markets, which could have a negative impact on our ability to access capital and additional sources of financing in the future.

In addition, we cannot predict the impact that the COVID-19 pandemic will have on our customers, employees, suppliers and distributors, and any adverse impacts on these parties may have a material adverse impact on our business. The impact of the COVID-19 pandemic may also exacerbate other risks discussed in Item 1A, “Risk Factors” section included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, any of which could have a material effect on us. This situation is continues to change rapidly and additional impacts may arise that we are not aware of currently.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-07-01 to 2020-09-30$287.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2020-01-01 to 2020-09-30$886.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-07-01 to 2020-09-30$131.9mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2020-01-01 to 2020-09-30$401.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-07-01 to 2020-09-30$155.1mus-gaap:GrossProfit
Gross profit9 months2020-01-01 to 2020-09-30$485.0mus-gaap:GrossProfit
Research and development3 months2020-07-01 to 2020-09-30$650.0kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$2.1mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-07-01 to 2020-09-30$19.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2020-01-01 to 2020-09-30$50.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-07-01 to 2020-09-30$135.4mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30$432.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$22.5mus-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$69.0mus-gaap:InterestExpense
Income tax3 months2020-07-01 to 2020-09-30$18.1mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-01-01 to 2020-09-30$61.8mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-07-01 to 2020-09-30$94.2mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30$309.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-07-01 to 2020-09-30$0.35us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2020-01-01 to 2020-09-30$1.15us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-07-01 to 2020-09-30$0.35us-gaap:EarningsPerShareBasic
Basic EPS9 months2020-01-01 to 2020-09-30$1.15us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-07-01 to 2020-09-30267,279,555 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2020-01-01 to 2020-09-30267,920,890 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2020-01-01 to 2020-09-30$416.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$30.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2020-07-01 to 2020-09-30$948.0kus-gaap:PaymentsOfDividends
Dividends paid9 months2020-01-01 to 2020-09-30$7.6mus-gaap:PaymentsOfDividends
Share repurchases9 months2020-01-01 to 2020-09-30$30.1mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-09-30$158.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$657.6mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$1.47bnus-gaap:Assets
Current liabilitiesAt period end2020-09-30$212.1mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-09-30$1.56bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2020-09-30$147.0kus-gaap:LongTermDebtCurrent
Short-term borrowingsAt period end2020-09-30$147.0kus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2020-09-30−$472.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000931148-20-000150. Last ingested by Listed: Nov 10, 2026, 00:15 ET. Listed shows no prices and gives no investment advice.